Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Advance registration for the 57th ASH Annual Meeting is now open.
Applications are now available for the MMSAP, an 8-to-12 week research experience for students in their early years of medical school.
Attend a complimentary CME summit in New York or Tampa on the diagnosis and clinical care of MDS jointly hosted by ASCP, ASH, and the France Foundation.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
As the world’s largest professional society
concerned with the causes and treatment of blood disorders, the American
Society of Hematology represents more than 14,000 members, many of whom depend
on funding from the National Institutes of Health to conduct cutting-edge
research that results in better treatments and cures for millions of patients
with blood diseases and cancer worldwide.
A study published online in Blood, the Journal of the American Society of Hematology, reports that brentuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.
The American Society of Hematology (ASH), the world’s largest professional organization dedicated to the causes and treatments of blood disorders, will bring together practitioners from around the world for the ASH Meeting on Hematologic Malignancies, September 17-19 in Chicago. The meeting will feature the top experts in the field, who will share their strategies for caring for patients with hematologic malignancies.
Pharmaceutical Media Inc. has been selected by the American Society of Hematology (ASH) as the advertising sales representatives for its journal Blood and annual meeting properties, effective January 2016.
On August 28, the Health Resources and Services Administration (HRSA), which is responsible for administering the 340B program, issued
that is intended to clarify and in some cases establish rules for participating in the program. The proposed guidance demonstrate some of the administrative difficulty of the program for both participants and the government monitors.
In compliance with the Best Pharmaceuticals for Children Act (BPCA), NIH published a list of therapeutics identified by the agency as the highest priority for study in pediatric populations. The BPCA requires sponsors of drugs for adult indications to study pediatric indications if a disease occurs in children. NIH must update its priority list every three years.
The National Heart, Lung and Blood Institute (NHLBI) released its draft strategic research priorities and is requesting additional input from the scientific community by August 28, 2015. The strategic planning process aims to identify compelling questions and critical challenges that should be addressed within the next decade. ASH submitted several research recommendations based on the ASH Agenda for Hematology Research and ASH Sickle Cell Priorities and is pleased to see many of them incorporated into the NHLBI's draft strategic research priorities. All ASH members are encouraged to review and comment by the deadline. Please see link above for more details.
On July 8, 2015, the Centers for Medicare and Medicaid Services (CMS) released its
governing payments for physician services and other associated policies covering the calendar year of 2016. This is the first physician fee schedule proposed rule following
the passage of the Medicare Access and CHIP Reauthorization Act (MACRA), which eliminated the sustainable growth rate formula that had long mandated cuts each year. Please follow the link above to learn more.
The 2015 MMSAP/MRI winners discuss their research and mentor experience.
Dr. Dawson talks about his journey as the inventor and developer of a standardized evacuated "tube" for blood specimen collection.
Dr. Rajkumar discusses how Dr. Robert Kyle started and developed the Multiple Myeloma Program at the Mayo Clinic. Dr. Kyle reflects on the success of the program for over 50 years.
Drs. Gale, Bennett, and Hoffman discuss factors hematologists must keep in mind when diagnosing patients with therapy-related AML or MDS, in order to prevent incorrect therapy decisions.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology